Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 60Neoplasm Metastasis 5Prostate Cancer Metastatic 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3Adenocarcinoma 3Prostate CA 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Recurrence 1Radiation Injuries 1Prostatic Diseases 1PSA Level Greater Than 0.03 1Oligometastatic Prostate Cancer 1Neoplasms 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Lymphatic Metastasis 1Intraprostatic Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1

Interventions

enzalutamide 2Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Sensitive Prostate Cancer × Androgen Antagonists × 1 year × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡